The latest: Ascletis Pharma Inc. (1672.HK) said on Monday the U.S. Patent and Trademark Office (USPTO) has granted it a patent for its oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including Covid-19, monkeypox and respiratory syncytial virus (RSV).

Looking up: Ascletis has become the first Chinese biotech company granted a U.S. patent for a self-developed oral viral polymerase inhibitor and its derivatives, which will be commercially protected until 2042.

Take Note: ASC10 is only in clinical trials for the treatment of the Covid-19 and monkeypox viruses, and the company says there is no guarantee that the drug will eventually be successful.

Digging Deeper: Ascletis self-developed ASC10 and has full global rights for the drug. Phase 1 clinical data showed ASC10, which is used as an oral drug for Covid-19, was safe and well tolerated in Chinese subjects. Preclinical studies have also shown the drug induces broad-spectrum antiviral activity against a variety of viruses, including monkeypox. As a result, Ascletis has filed several patent applications worldwide for ASC10 and its use in the treatment of viral diseases.

Market Reaction: Ascletis Pharmasurged 28.4% on Tuesday morning after the announcement and closed up 26.9% at HK$4.39 by the midday break. The stock now trades around its 52-week midpoint.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Agora makes real time engagement technology

AI powers Agora back to revenue growth

The maker of real-time engagement technology is benefitting from new demand for products like real-time online virtual tutors and talking toys Key Takeaways: Agora reported a slight revenue increase in…